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30.1 LABORATORY ANIMALS AS TOOLS IN
BIOMATERIALS TESTING
Animal models have been extensively developed in the last decades in biomedi-
cal field. Their use has shown particular relevance in fields such as cell biology,
genetics, anatomy and development, biochemistry, infection and immunity, can-
cer research, drugs and vaccine development, tissue engineering and regenerative
medicine.
Despite major advances regarding in vitro models aiming to mimic the complex-
ity and cellular interaction existing within tissues [1–3], in vivo testing is essential
to safely investigate the biological performance of newly developed devices when
implanted in a living system. A better characterization of such response at cellu-
lar and molecular level is required, and has been extensively investigated in the last
decades [4–7]. However, the complexity of in vivo responses to implanted biomate-
rials renders this assessment a challenging issue to address.
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TABLE 30.1 Criteria to consider when choosing the adequate animal model to
characterize biomaterials
Biomaterial Animal Other
Size Species and strain Housing conditions
Shape Age Technical expertise
Degradation time frame Sex Surgical procedure
Degradation products Genetic background Anesthetics
Physiological status Analgesics and antibiotics
Metabolism Clinical assessment
Lesion to treat Euthanasia/sacrifice methodologies
Tissue to regenerate Type of in vivo and post mortem analysis
Budget
As an experimental hypothesis is set, the animal model chosen should achieve
the expected consistent answers, and also mimic the human clinical situation, which
enables a correct extrapolation to be made.
The application of specific criteria to choose the adequate animal model is manda-
tory in biomedical research. Particularly in the field of testing biomaterials, it is of the
utmost importance to have in consideration crucial aspects related to the biomaterial
to be tested; these are summarized in Table 30.1. Additionally to these basic criteria,
other important issues must be considered in functional animal models related to the
specific tissue to regenerate, such as bone or cartilage, as will be discussed later in
this chapter.
The basic criteria are all interconnected, and it is impossible to consider them
separately when the researcher needs to choose the animal model to characterize a
biomaterial. There are compendia that can guide researchers to select adequate mod-
els according to the specific aim of their research [8]. However, previous knowledge
of animal science and welfare must be considered in order to accurately read and
understand the information provided in these books.
The initial in vivo evaluation of biomaterials is usually, but not limited to, the
assessment of the inflammatory and host response to the implanted material. At this
stage of evaluation, the size and shape of the material are only important in consid-
ering a suitable animal to accommodate the implant, and in which a response can be
observed and measured. On the other hand, when functional studies are considered,
the size and particularly the shape must mimic the final aspect of the material to be
used in human medicine as much as possible. For instance, this applies to biomate-
rials for tissue regeneration (further discussed in section 30.3: the cartilage and bone
specific situations). In the evaluation of inflammation and host reaction induced by a
biomaterial, it is also important to know the material degradation time frame, as well
as its degradation products, that can induce toxicity in the host. Bearing in mind the
specific characteristics of the produced biomaterial, one must then consider the dif-
ferent types of animals which may be adequate models for the study. Rodents are tra-
ditionally used to assess inflammation; however other species can be used. Age, sex,
genetic background and metabolismmust be considered when analysing the obtained
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results in order to have a better correspondence with humans. The pathophysiological
status is also an important condition, mainly in functional evaluation of the biomate-
rial (further discussed in section 30.3); healthy vs ill (or induced pathology) animals,
although for inflammation and host reaction evaluation, healthy animalsmust be used.
The lesion to treat and/or the tissue to regenerate are criteria that must be addressed
when choosing the functional animal model (further discussed in section 30.3).
Despite the issues related with the biomaterials to characterize and the animal itself,
other considerations are important to deal with, such as housing conditions and tech-
nical expertise, surgical procedures, pharmacological conflicts (e.g. anaesthesia, anal-
gesia and antibiotherapy may interfere in the host reaction evaluation), the method of
killing at the endpoint of the experiment or eventual euthanasia procedure if needed
at any time during the experiment. Also, the type of analysis required (in vivo and/or
post mortem) may limit the choosing of the animal (e.g. for in vivo luminescence,
large animals cannot be used and if histologic processing of the samples is required
at the endpoint). Finally, the budget is a recurrent issue that may force researchers to
choose less costly animals (e.g. rodents) in detriment of ovine or caprine species but,
of course, the results must be interpreted accordingly.
30.2 INFLAMMATION AND HOST REACTION
The induced host tissue trauma and the inflammatory process resulting from the
implantation of a medical device [9–12] are of utmost importance for a success-
ful outcome. Features of a chronic inflammation are usually attributed to the host
response towards the implant, while an early acute inflammatory response is mainly
endorsed by the implantation procedure. Nevertheless, no matter what, the final pur-
poses of inflammation are to destroy (or control) the invading agent, to initiate the
repair process, and to re-establish tissue function as a continuous event [11, 13].
As a wound is created, coagulation takes place in the context of acute inflamma-
tion. Simultaneously, the complement system, which has the capability to distinguish
‘self’ from ‘nonself’ [14, 15] is activated [11, 16, 17] (Fig. 30.1). The interaction of
plasma proteins such as immunoglobulins [12] and fibrin [11,12,16,17] with the sur-
face of the material, or through an inadequate down-regulation of convertase, which
enables C3b binding to plasma proteins, such as albumin, immunoglobulin G (IgG)
and fibrinogen [17], is the main factor responsible for this activation (Fig. 30.1). In
addition, adsorbed proteins onto the surface of the implanted materials act as strong
chemoattractants to polymorphonuclear neutrophils at an early stage and blood
monocytes within 24 hours (Fig. 30.1). Macrophages derived from blood monocytes
continue the phagocytic work initiated by neutrophils [11, 18], although they might
also act as antigen-presenting cells after processing the material [12], instigating
specific immunological responses [11] in which lymphocytes also participate [11].
In general, the formation of foreign-body giant cells (FBGCs) indicates the transition
to a chronic inflammatory process [10,19]. However, the same features may co-exist,
attesting simultaneous development of acute and chronic inflammation [20]. As the
FBGCs persist, unable to resolve the inflammation, cytokines and chemokines are
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FIGURE 30.1 Schematic representation of the major events occurring from the creation of
an incision, to host cell activation and cytokine release, which determine the ongoing inflam-
matory process. Once a wound is created, the microvasculature is affected and coagulation
takes place in the context of acute inflammation. The complement system is activated mainly
by the interaction of plasma proteins (e.g. immunoglobulins and fibrin) with the surface of the
material, or through an inadequate down-regulation of convertase, which enables C3b binding
to plasma proteins (e.g. albumin, immunoglobulin G (IgG) and fibrinogen). Then, the adsorbed
proteins onto the surface of the implanted materials act as strong chemoattractants to polymor-
phonuclear neutrophils, blood monocytes which will attract lymphocytes and other inflamma-
tory/immune cells. In their turn, these host cells secrete anti- and/or pro-inflammatory media-
tors (cytokines an antibodies) that will affect the ongoing inflammatory process.
released, inducing delayed-type hypersensitivity and forming a granuloma at the
injury/implant site [4, 21, 22]. Granuloma formation is often a reason for implant
rejection [23–27], or additionally may induce latent autoimmune diseases [28].
Some authors argue [23, 29–31] that at the implant site, the foreign body induces
chronic stress bringing forward the formation of granulomas. However, that is not
always true and implants can be well-tolerated and integrated in the host tissue
without eliciting a persistent acute inflammation [32]. Additionally, when collagen
synthesis is likely to surpass its degradation [33], excessive fibrotic tissue surrounds
the implant impeding the interaction of the host with the implanted material
[22, 33–35]. Therefore, thick fibrotic capsule formation is considered as a detrimen-
tal consequence of biomaterial implantation and a negative feature needed to be
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overcome, in order to improve the host reaction and eventually avoid rejection of the
implant.
Ideally, an implanted biomaterial would interact with and integrate with the host
tissue [36, 37], allowing the functional re-establishment and a complete recovery of
the injured tissue. The resolution of inflammation with concomitant integration of
the implant in the host tissue precedes the healing process. In a tissue engineered
construct where the scaffolding material works as a temporary structure, the constant
mutation of the implanted material will influence the reaction from the host. Addi-
tionally, the release of degradation products should not adversely interact with the
host and should be physiologically discarded. Moreover, the presence of cells and
bioactive agents influencing the properties of the polymeric structure complicate the
ideal scenario and raises further concerns still to be overcome.
30.2.1 Host Reaction Models
The initial screening prior to the indication of biomaterials for clinical applications
implies the validation of the safety of the biomaterials, as well as their degradation
products when in contact with the host tissue. This evaluation has been traditionally
performed in rodent (mice and rats) subcutaneous, intraperitoneal and intramuscular
implantations models [38–44].
Subcutaneous, intramuscular and intraperitoneal murine models are useful tools to
evaluate the effect of anti-inflammatory and inflammatory mediators, such as dexam-
ethasone [45], nitric oxide [46], tumor necrosis factor-alpha (TNF-α) and interferon-
gamma (IFN-γ) [47], vascular endothelial growth factor (VEGF) and fibroblast
growth factor (FGF) [48] towards host tissue at the implant site. Generally, assessed
parameters are inflammatory tissue response, foreign body reaction (FBR), phago-
cytic potential of macrophages and eventual giant cell formation, fibrotic capsule
formation and thickness, as well as vascularization in the surrounding tissue at the
implantation site.
Despite the effort of researchers to use adequate models for their experiments, it
is difficult to draw valuable information due to the differences in model and reac-
tion mechanisms [47, 48], in carrier materials, or even in implanted material surface
properties [45–48].
It is important to consider the different types of host reaction that can be elicited
after the implantation of biomaterials, as was stated previously in this chapter. The
primary acute inflammatory response is the most evaluated reaction after the implan-
tation of biomaterials [37,38,49,50]. After this initial inflammatory reaction, different
scenarios can occur:
(a) The implanted biomaterial degrades in a relatively short time frame (while
the inflammatory response is still being observed) and the degradation prod-
ucts may cause inflammation themselves, or these products are metabolically
excreted by the host;
(b) The biomaterial does not degrade in the course of the inflammatory reaction
and is surrounded by a fibrotic capsule and no other interaction with host cells
is observed (foreign body reaction) or;
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(c) The host does not surround the biomaterial with the fibrotic capsule, but is not
able to degrade it, therefore two situations may arise:
(i) the host immune system is activated into setting up a chronic reaction or,
(ii) the acute inflammation persists and a nonhealing wound appears at the
implantation site.
Most of the biomaterials that reach the in vivo evaluation stage are expected not
to induce either chronic or persistent acute inflammatory responses. Regarding the
degradation profile it may depend on the specific application. Nevertheless, the most
frequently used host reaction models (subcutaneous, intramuscular and intraperi-
toneal) are also able to provide information on those types of reaction, particularly the
chronic inflammatory response [37, 38, 49, 51] and the integration of the biomaterial
within the host tissue after long periods of implantation [36,37,52–54]. Host reaction
models must also be capable of providing information regarding local [37,38,55] and
systemic [38,55,56] responses induced by the implantation of biomaterials. Regard-
less of the intended final application of biomaterials, subcutaneous and intramuscu-
lar implantation models offer information about the direct effect of the biomaterial
at the implant site [37,38,42,43,55], whereas intraperitoneal injections or implanta-
tions provide data on the effect in the abdominal organs, such as spleen, liver, kidney,
mesenteric lymph nodes and related adipose tissue [38,55,56], as an indication of the
systemic influence of the biomaterials on the host. Moreover, intraperitoneal models
are the most suitable for evaluating cell recruitment and activation status [56, 57], at
short [56, 58–60] and long periods [54, 56] of reaction. Besides injection of particle
suspensions [55, 56], these models also permit materials implantation [54, 58–60],
allowing establishment of a parallel between the implant/host interface analysis and
the surrounding cellular milieu. The cytokine profile resulting frommaterials implan-
tation is an example of an extremely powerful measure of this crosstalk. In fact, the
cytokines in exudate samples are released by recruited cells which received the infor-
mation from mediators, in its turn, secreted by surface adherent cells [61, 62]. Addi-
tionally, direct cell response to the implant surface may elicit the release of several
reactive species, which either induce cell death or concomitant secretion ofmediators,
such as new reactive species.
Modification of the classical models of subcutaneous implantation, such as cage
implants [7, 63], air pouches [41, 64, 65] or dorsal skinfold chambers [66] have
also demonstrated reliable results regarding the interplay between direct and indi-
rect material surface reactions. Cage implant models were shown to be useful for
identifying recruited and adherent cell types [63] as well as macrophage fusion into
FBGCs [7] and cytokine release [61] in response to implanted materials, either in rats
[7,63] or mice [61]. Moreover, the observation of leukocyte recruitment and accumu-
lation was possible in a dorsal skin fold chamber [66], using intra-vital fluorescence
and avoiding the killing of animals at different experimental time periods.
Additionally to the previously referred aspects, it has been mentioned that dif-
ferences in host reaction can be related to sex dimorphism or with species, but few
studies [67, 68] have really addressed these questions. Only subtle differences were
observed between male and female, regarding the inflammatory cells pattern and con-
nective tissue, as well as tumor necrosis factor alpha (TNF-α) and interleukin-1 beta
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(IL-1β) secretion after subcutaneous implantation of a smooth peroxide-catalyzed
polydimethylsiloxane (PMDS) in mice [67]. In terms of the species, Khouw and co-
workers [68] showed that rats were able to overcome a foreign body reaction more
effectively than mice, probably due to different recruitment kinetics, but stroma for-
mation and calcification was more abundant in mice compared with rats [68].
Nevertheless, host reaction evaluation should not be limited to the assessment of
inflammatory reaction, particularly if the developed device is aimed to remain in
the host for longer periods and/or if it degrades during the implantation time. For
these reasons, the immune response must also be evaluated before pursuing studies
with the produced biomaterial. An adequate method to assess in vivo immune stim-
ulation by biomaterials is to perform repetitive implants (rat subcutaneous [69] or
intraperitonea l [54] model) and analyse the host–tissue response, immune cells and
antibody production [54, 69]. The development of surfaces with less immunogenic
potential [54,58,70–72] is one of the most important goals when producing biomate-
rials for biomedical applications. In fact, one of the researcher’s great beliefs is that
the implant/host interface is a key issue to identify tissue reaction to implants. Despite
the effort in constructing and validating in vitro systems to predict the whole body
reaction to the implants, there is not a reliable system that provides conclusive results
on the assessment of the immunogenic potential of biomaterials for biomedical appli-
cations (see Chapter 26 for further details on immunogenic issues).
30.3 ANIMAL MODELS FOR TISSUE ENGINEERING
In vitro testing systems are inevitably limited in their capacity to recreate the com-
plex in vivo environment. Therefore, these assays are unable to predict accurately the
in vivo performance, particularly in the context of tissue engineering and regeneration
of functional tissues. Factors such as the role of angiogenesis in newly formed tissue,
immune reaction to implanted biomaterial and functional properties of the graft, are
unable to be assessed in a an in vitro context. Thus, in a later stage of development it
is critical to test the developed strategies in vivo.
The choice of an appropriate animal model will depend upon the question asked.
Animal testing comprises a midway step between in vitro studies and human clinical
trials, which precede real clinical application. Experimental design allows selection
of species and standardized operative and analysis procedures. Animal models are
simplified representations or analogues possessing the same or similar functions and
structures as the system of study.
In vivo experimentation design in tissue engineering and regenerative medicine is
demanding, being necessary to balance all variables and decide which animal model
better suits the specific goals of the experiment. Themaintenance of animals is expen-
sive and variations within the same group may be larger compared with those that
are found in small laboratory animals. A countless number of variables need to be
addressed to assure that the chosen model is the most appropriate to evaluate a spe-
cific situation. Consequently, variables should be minimized and very well controlled
to reduce random effects and to ensure as much as possible statistical significance.
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The variables are the physical condition of the animal (nutritional status, diet, age,
sex), anesthetics and analgesics, type of defect (location, use of fixation) and, finally,
the methodologies used to assess the sample collection and characterization.
Another important parameter is the inclusion of controls in the experimental
design. These controls should contain a material already in clinical use, a control
of an empty defect to prove that the bone defect is not able to regenerate by itself,
and if it is using cells, the material without cells [73, 74].
The first approach generally chosen is the ectopic model in a small animal, usually
rodents (mouse or rat). Ectopic is derived from the Greek word ektopos, meaning
‘away from the place’, and it refers to studies where ossification occurs outer the
original places. On the other hand, orthotopic tissue formation is derived from the
Greek word orthos, which means ‘straight or right’, and it refers to tissue formed
at the normal place, i.e. bone in a bone location or cartilage in a cartilaginous area.
The most simplistic of ectopic models is the subcutaneous implantation. Incisions
are made in the dorsum of the animal, to prevent that animals disturbing their own
sutures, in order to maintain the biomaterials/cells in place. The other type of ectopic
model is the intramuscular implantation. Usually for small animals, use of the hind
limb is recommended.
Moreover, if the aim is to evaluate tissue engineered constructs that include human
cells, immunocompromised mice/rats are used, because these animals are genetically
modified to not develop thymus, being unable to produce mature T lymphocytes, key
immune cells in graft/implant rejection [75, 76].
Typically, researchers start with a smaller model like mouse or rat because of the
low variations among animals, ease of handling and availability, cost efficiency and
also because it is easier to compare results between a wealth of experiments reported
in the literature. Independently of the model chosen, all results must be interpreted in
light of the experimental model, and caution must be taken before extrapolating valid
conclusions to humans.
In the next sub-chapters the animal models used for cartilage (section 30.3.1) and
bone (section 30.3.2) regeneration will be described.
30.3.1 Cartilage Tissue Engineering
There are several animal models described in the literature used to conduct in vivo
research on natural based biomaterials for cartilage regeneration. Cartilage can be
classified, depending on the composition of the matrix, into elastic, fibro-cartilage,
fibro-elastic and hyaline. A specialized type of hyaline cartilage, called ‘articular car-
tilage’, covers the joints. Hyaline cartilage provides a low friction surface, with high
compressive strength and wear-resistant under normal circumstances [77].
The most important factors in the choice of an animal model for cartilage repair
might be the size of the joint and cartilage thickness, as well as the animal size.
The majority of the in vivo studies with rodents for cartilage tissue engineering,
involves the use of heterotopic chondrogenesis models implanting biomaterials sub-
cutaneously. Basically these models consist of making an incision in the dorsum
of the animals and introducing the biomaterial (3D scaffold), or injecting it (gel)
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subcutaneously in each corner (up to four biomaterials are used) of mice. Immuno-
compromised animals enable conducting studies with allogeneic or xenogeneic cells
with or without biomaterials. The small size of the joints and thickness of articular
cartilage of these animals enable its use in other type of assay. Overall, rodents are
cost-effective animal models that can be used for preliminary in vivo assessment of
cartilage regeneration for further investigation in large animal models [78,79]. In the
natural biomaterials field, there are several reports of these types of animal model.
A study with chitosan hydrogels injected subcutaneously in the dorsum of nude
mice with or without newborn bovine primary articular chondrocytes, was allowed
to develop for 7 or 9 weeks [80]. Wang et al. [79] used an alginate scaffold prepared
using a microfluidic device seeded with porcine chondrocytes and implanted in the
dorsal subcutaneous site of SCID mice. Controls were used by placing a blank scaf-
fold without cell seeding in two animals per time point. The recipients were killed
at 2, 4, and 6 weeks after transplantation [79]. In another study, recombinant human
type I and II collagen gels were injected with or without bovine chondrocytes into
the back of nude mice for 6 weeks [81].
Typically an induced cartilage defect is an osteochondral defect that consists of
focal damaged areas of cartilage and injury of the adjacent subchondral bone. An
example of this type of defect in rats, is the study of Dausse et al. [82], where the
authors used full thickness cartilage defects of 1.3 mm drilled in femoral trochlea
of rats. Filling of the resulting defect was achieved by injection of a hyaluronic acid
hydrogel or insertion of alginate sponges, with or without autologous chondrocytes.
The contralateral knee constituted an individual control of surgery, but without carti-
lage lesion [82].
In the early years of cartilage tissue engineering research, the rabbit was a popu-
lar model for osteochondral repair [83–85]. As the rodent model, these animals are
genotypically similar, relatively inexpensive and easy to handle, which allows use of
a significant number of animals in one experiment. Furthermore, rabbits reach early
skeletal maturity at 9 months.
Cross-linked type I and type II collagen matrices, with and without attached chon-
droitin sulfate, were implanted into full-thickness defects in the femoral trochlea of
adolescent rabbits. Two full-thickness defects of 4 mm per 1 mmwere created in each
trochlea. Empty defects were used as controls. The tissue response was evaluated at
4 and 12 weeks [85]. Autologous adipose stem cells and articular chondrocytes com-
bined with gellan gumwere injected in rabbit knee 4 mm per 1 mm full thickness size
defects. Controls with defects filled with gellan gum without cells and empty defects
were performed. The experiments were conducted for periods of up to 8 weeks with
data collection points at 1, 4, and 8 weeks [83]. The lapine model is quite controver-
sial, because of the endogenous healing potential of cartilage in rabbits [86]. Research
on the cell origin of tissue repair in full-thickness cartilage defects concluded that the
repair mechanism was mediated entirely by proliferation and differentiation of MSCs
from bone marrow without participation from adjacent articular cartilage [87].
The pre-clinical evaluation of an articular regenerative strategy requires confirma-
tion in large animals, such as sheep or goat, whose knee anatomy is similar to humans
[88]. However, goats have cartilage proportions and subchondral bone involvement
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closer to humans [88]. The current surgical procedures to treat chondral lesions are
aimed towards providing access for endogenous chondrogenic cells to the defect, such
as microfracture. Subchondral bone is drilled and bone marrow cells derived from the
bone marrow clot the defect, forming cartilage. However, the repair mechanism pro-
motes the formation of nonfunctional fibrous tissue or fibrocartilage. Dorotka et al.
[89] used an ovine model combined with microfracture treated with the matrix com-
prising type I, II, and III collagen, either unseeded or seeded with autologous chon-
drocytes. The animal study described here included 22 chondral defects in 11 sheep,
divided into four treatment groups: A – microfracture and collagen matrix seeded
with chondrocytes; B – microfracture and unseeded matrices; C – microfracture; D –
untreated defects. All animals were killed 16 weeks after implantation, and a his-
tomorphometrical and qualitative evaluation of the defects was performed. Only the
matrices seeded with autologous cells in combination with microfracture were able to
facilitate the regeneration of hyaline-like cartilage. In a study by Lind and co-workers
[90], a collagen membrane in combination with autologous chondrocytes or autolo-
gous cartilage chips were implanted for 4 months in a goat femoral condyle 6 mm
full thickness cartilage defect model [90].
30.3.2 Bone Tissue Engineering
As previously described, in an ectopic study the constructs are implanted into a non-
bone related anatomic location of the animal body, such as subcutaneously [91, 92].
This model is also interesting for determining whether a scaffold has adequate proper-
ties namely porosity and interconnectivity, to allow tissue ingrowth and neovascular-
ization. It is important to draw conclusions about the biodegradation of the implanted
material, in terms of degradation products and also about the host immune response.
The purpose of using such a model is to conclude about the ability of the constructs
to form ectopic bone and also to verify osteoinductivity, i.e. the ability of the scaffold
to induce proliferation of undifferentiated stem cells, as well as their differentiation
into the osteogenic lineage [75, 76, 78, 93, 94].
It is important to emphasize the concept of critical-sized defect (CSD), defined
by an intraosseous wound that will not heal spontaneously during the lifetime of
the animal [95]. However, the minimum size considered to be a critical size defect
is not completely clear. The defect is not only defined by size, being dependent on
diverse variables such as, type of species, anatomic location, among many others
[96]. Guidelines are available for the dimensions of implants based on the size of
the animal, type of bone chosen and implant design, in order to avoid pathological
fracture of the test location [74]. Several types of bone defects can be used such as
cranial, segmental, partially cortical and cancellous bone.
Bone regeneration must not only be evaluated in animals treated with the tissue
engineering strategy, but also in sham-operated animals (negative controls) and in ani-
mals treated with autologous corticocancellous bone grafts (positive controls), which
still remain the gold standard material in bone tissue engineering.
Different bone locations can be subjected to load or nonload bearing (e.g. femur or
calvarial, respectively). The type of animal can be small (mouse or rat) [97–101] or
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large (rabbit, sheep, goat, dog or primate) [102–109]. One of the most frequently used
models is the non-load bearing calvarial bone defect. This bone is flat, allowing the
creation of a circular defect, by the use of a dental trephine with a dental drill against
the superficial aspect of the calvarium. The dura mater and the overlying skin provide
enough fixation of the scaffold and it is very important to keep the dura intact because
the healing of a calvarial defect is dependent on the presence of this structure. The
model has been systematically studied and is very well established [95, 110–112],
using rat [113, 114] or mouse [97, 98]. It can be also applied to larger animals, like
rabbit [115–117] or sheep [118].
Natural biomaterials have been tested in rat calvarial bone defect models [114,
119, 120]. Chitosan and chitosan hydrochloride gels were tested in 8 mm calvaria
defects in rats for 15 and 60 days. Blood clot was used as a control. The authors con-
cluded that chitosan and chitosan hydrochloride biomaterials did not promote new
bone formation in critical size defects made in rat’s calvaria, with assorted degrees
of inflammation [120]. The same animal model was used in another study with chi-
tosan/tricalcium phosphate (TCP) sponges used as carriers for platelet derived growth
factor (PDGF-BB) delivery. Chitosan/TCP sponges with and without PDGF-BBwere
implanted for 2 and 4 weeks, and the sponge carrier without PDGF-BB promoted
osseous healing of the rat calvarial defects compared with controls (empty defects).
The addition of PDGF-BB to the carrier further enhanced bone regeneration [119]. In
another report, with the same animal model, fluorescent-labeled cells (MSCs) were
encapsulated in a chitosan gel with or without bone morphogenic protein 2 (BMP-2).
Five experimental groups were tested for 8 weeks: (1) chitosan gel; (2) gel loaded
with MSCs; (3) gel loaded with BMP-2; (4) gel loaded with both MSC and BMP-2;
(5) control group, the defect left untreated. The injectable form of chitosan gel, MSC,
and BMP-2 enhanced more bone formation compared to the others [114].
Mouse cranial defect is also used to assess the capacity of natural biomaterials to
promote bone regeneration [75, 76, 98]. Alginate scaffolds with or without octacal-
cium phosphate (OCP) were implanted in mouse calvaria critical-sized defects for
21 days [98]. Studies with cells, usually involve human derived cells, and for that
reason immunocompromisedmice (nudemice) are used. Undifferentiated human adi-
pose tissue stem cells (hASCs) loaded in starch-polycaprolactone (SPCL) scaffolds
were implanted in a critical-sized nude mice 4 mm calvarial defect, for 8 weeks. Cra-
nial defects were either left empty, treatedwith an SPCL scaffold alone, or SPCL scaf-
fold with hASCs. Improved new bone formation was observed in SPCL with hASCs
comparedwith control groups that showed little healing [75]. In another report, Costa-
Pinto et al. [76], used human bone marrow mesenchymal stem cells (hBMSCs) cul-
tured in vitro for 2 weeks in osteogenic differentiation conditions chitosan fiber mesh
scaffolds, and further implanted for 8 weeks in 5 mm cranial defects of nude mice.
Scaffolds alone and empty defects were used as controls. Retrieved implants showed
good integration with the surrounding tissue and significant bone formation, more
evident for the scaffolds cultured and implanted with human cells (Fig. 30.2) [76].
However, since calvaria do not allow for the assessment of biomechanical loading
at the interface of the implanted material, alternative anatomical load-bearing loca-
tions should be selected, such as mandible [121], femur [99,100,122] or tibia [123].
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FIGURE 30.2 Micro-CT analysis of calvaria defects in nude mice after 8 weeks of implan-
tation of chitosan-polybutylene succinate scaffolds with or without cells. E, empty; Sc, scaf-
fold alone; Sc + MSCs, scaffolds with human bone marrow MSCs pre-cultured in vitro in
osteogenic medium.
Natural biomaterial starch with polycaprolactone double layer scaffolds, functional-
ized with silanol groups (SPCL-Si) or without (SPCL), were tested in a mandibu-
lar defect rodent model [121]. Commercial collagen membranes and empty defects
were used as positive and negative controls, respectively. After 8 weeks of implanta-
tion SPCL-Si scaffolds induced significantly more bone formation, when compared
to collagen membrane and to the empty defects, although these had a similar perfor-
mance when compared to the SPCL scaffolds [121]. In another study, starch-based
scaffolds specifically, a blend of corn starch and ethylene-vinylalcohol (SEVA-C), the
same composition coated with a biomimetic calcium phosphate (Ca-P) layer (SEVA-
C/CaP), and a blend of corn starch and cellulose acetate (SCA) were implanted into
rat distal femurs proximal to the epiphyseal plate, for 1, 3, or 6 weeks. No bone con-
tact was observed with SEVA-C at any time point, only transitory bone contact was
observed with SEVA-C/CaP at 3 weeks, while SCA exhibited direct bone contact at
6 weeks [100]. Natural based silk fibroin scaffolds with hBMSCs pre-differentiated
into the osteogenic lineage were evaluated in critical sized mid-femoral segmental
defects in nude rats, for 8 weeks. Scaffolds without cells, and with undifferentiated
cells, as well as empty defects were also tested. The group of animals with the silk
scaffolds and pre-differentiated cells presented the best results in terms of bone for-
mation [99].
The last stage of pre-clinical trials of a bone tissue engineering strategy should
be performed in animals that are believed to be more similar to humans, in terms of
metabolism, physiology, anatomy, etc. Small animals present several disadvantages
in terms of anatomical disparity with humans, and difficulties in carrying out ortho-
pedic procedures because of their small size and kinematic differences. For example,
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a femur defect in rats [124–126] is believed to heal faster that in larger animals
[111]. However, in a study where the authors compared the bone ingrowth using the
same chamber, in rats and in goats, no significant differences were observed between
the two animals [127]. Surgeries involving load-bearing conditions, involving
stabilization with internal or external fixation devices, require the presence of experts
to perform the procedure. Larger animals are significantly more costly and more
difficult to work with. Despite these issues, the final pre-clinical tests should be
performed in large animals, subjected to load bearing comparable to the human case.
For this purpose, sheep or goats may be good options. Both animals have a similar
metabolism and bone remodeling rate to humans, as well as a comparable weight
[106,118,128–130]. Large animals can be also used to test biomaterials in nonloading
areas, such as intramuscularly or intra-cortically [128]. Biodegradable starch-based
materials, starch/ethylene vinyl alcohol blend (SEVA-C) and a composite of SEVA-
C reinforced with hydroxyapatite (HA) particles were evaluated in intramuscular
and intracortical (four holes of 5 mm diameter were drilled in the lateral cortex,
where the scaffolds were pressed into the holes) bone implantation models in
goats [128].
SPCL natural based scaffolds seeded and cultured with goat marrow stromal cells
(GBMCs) 7 days in osteogenic differentiation conditions, were implanted in noncrit-
ical defects (diameter 6 mm, depth 3 mm) in the posterior femurs of goats, using an
autologous model. Drill defects alone and defects filled with scaffolds without cells
were used as controls [122].
30.4 FINAL REMARKS
From what has been previously pointed out it becomes relatively clear that the selec-
tion of an animal model it is not a straightforward issue. The particular case of inflam-
matory/host reaction evaluation adds additional challenges due to the high variance
between animals in the same experiment, which is also a rather usual observation. A
statistically representative approach, not only in the number of implanted materials,
but also in the number of tested animals, is crucial to reduce the standard deviation
for the results of the experiment, and to have confidence on the tissue response of
that particular species to the implanted biomaterials. However, the increased discus-
sion regarding the number of animals used in research, led to the establishment of
models that avoid animal sacrifice and limited data outcome. Bioluminescence and
transgenic animals represent a valuable combination in order to evaluate parameters,
such as inflammation and vascularization. These models allow a long time analysis
avoiding the killing of several animals at the intermediate time points. Within this
effort to reduce the number of animals, Ho and co-workers [131] were able to assess
the real-time in vivo inflammatory response to a subcutaneous implant of genipin-
cross-linked gelatine, by in vivo bioluminescence, in a transgenic mouse model car-
rying the luciferase gene driven by NF-κB-responsive elements. The movement of
host molecules is, in fact, an important issue to consider in the monitoring of the
inflammatory/immune reaction to implanted biomaterials. In that particular case, the
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nuclear factor- κB (NF-κB) is a nuclear transcription factor, critically involved in the
regulation of inflammatory cytokine production and, consequently, in inflammation
[132]. Likewise, in a dorsal skin fold chamber model performed in hamsters, is was
also possible to determine in vivo vascularization with intravital fluorescence without
killing the animal [66].
The shape and size of the biomaterial to be tested, as well as its final application,
are important features to have in consideration when choosing the animal model. For
example, for compact or scaffold material, subcutaneous or intramuscular implanta-
tion will be more suitable than the intraperitoneal implantation. This type of model
would be more appropriate for testing the reaction of materials suspended in solu-
tions, such as microparticles or nanoparticles.
The final intended use and function of the implanted biomaterial is also related to
the degradability issue. Generally, natural polymers undergo enzymatic degradation
and the degradation rate of a biomaterial is also linked to the type of response elicited
by the host tissues. Phagocytic cells are normally able to remove debris from the
tissue by engulfment and digestion, making the digestion of implanted materials an
important issue to consider. In some cases it is not the biomaterial itself that induces a
specific reaction, but the degradation products resulting from the concomitant action
of the cells in the device.
Although challenging, more importantly in all animal use for biomedical research,
in order to conduct the studies as accurately as possible, it is important to find or create
a model, which allows the most precise answers to experimental questions, as well
as a correct extrapolation to the human scenario.
No animal is ideal for every type of project in cartilage or bone research. As every
animal model has its advantages and disadvantages, a comprehensive analysis of each
available species needs to be conducted when planning an animal study. Cost effec-
tiveness, anatomy, maturity, and joint biomechanics as well as postsurgical protocol
must be taken into account. A model is relevant if experimental conditions and gener-
ated effects are linked. The experimental designmust therefore include the innovating
technique as well as negative and positive controls guaranteeing valid comparisons.
The research question ultimately drives the choice of animal model.
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